Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
Egmond, Elfi (Universitat Autònoma de Barcelona. Departament de Psicologia Clínica i de la Salut)
Mariño, Zoe (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Navinés, Ricard (Universitat de Barcelona. Institut de Neurociències)
Oriolo, Giovanni (Universitat de Barcelona. Institut de Neurociències)
Pla, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Bartres, Concepció (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Lens, Sabela (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Forns, Xavier (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Martin-Santos, Rocio (Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ribeirão Preto, Brazil)

Data:	2019
Resum:	Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i. e. , interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depression in a real-life prospective cohort of chronic hepatitis C patients treated with the new DAAs. The sample was recruited from a cohort of 91 patients with hepatitis C, of both sexes, with advanced level of fibrosis and no HIV coinfection, consecutively enrolled during a 6-month period for DAA treatment; those euthymic at baseline (n=54) were selected. All were evaluated through the depression module of the Patient Health Questionnaire (PHQ-9-DSM-IV), at three time points: baseline, 4 weeks, and end-of-treatment. The cumulative incidence (95%CI) of major depression and any depressive disorder during DAA treatment was 13% (6. 4-24. 4) and 46. 3% (33. 7-59. 4), respectively. No differences were observed between those patients with and without cirrhosis or ribavirin treatment (p > 0. 05). Risk factors for incident major depression during DAA treatment included family depression (relative risk 9. 1 [1. 62-51. 1]), substance use disorder (11. 0 [1. 7-73. 5]), and baseline PHQ-9 score (2. 1 [1. 1-3. 1]). The findings of this study highlight the importance of screening for new depression among patients receiving new DAAs, and identify potential associated risk factors.
Ajuts:	Instituto de Salud Carlos III PI15/00151
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Depression ; Direct-acting antivirals ; DAA ; Hepatitis C ; PHQ-9
Publicat a:	Brazilian Journal of Psychiatry, Vol. 42 (july 2019) , p. 72-76, ISSN 1809-452X

DOI: 10.1590/1516-4446-2018-0336
PMID: 31314868

5 p, 96.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Neurociències (INc)
Articles > Articles de recerca
Articles > Articles publicats